• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

2.300 -0.100 (-4.17%)
Streaming Delayed Price Updated: 2:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 Next >
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
July 24, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
July 21, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 15, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
June 24, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INDP),(NYSE:CATX),(NASDAQ:SLS),(NASDAQ:AUTL EQNX::TICKER_END 
Via FinancialNewsMedia
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
June 12, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Participate in Upcoming Investor Conferences
May 29, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
May 23, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
May 14, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
May 08, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
April 25, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
April 23, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
April 22, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 02, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
April 01, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
March 20, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
March 06, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Participate in Upcoming Investor Conferences
March 05, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
January 17, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Provides Business Updates and 2025 Overview
January 13, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
December 09, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
December 02, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
November 12, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
November 08, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
November 05, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
October 28, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
October 16, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
September 19, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
August 27, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 08, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
July 26, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap